

SRS 2026- Hollywood, FL- JULY 25th

SRS 2026 Uro-oncology program (Prostate Cancer)

The SRS Uro-Oncology Course aims to integrate multiple specialties, including urology, medical oncology, radiation oncology, radiology, pathology, and genomic medicine, to discuss the most contemporary and evidence-based approaches to the management of uro-oncologic patients. Our objective is to provide a multidisciplinary educational platform built on the highest level of clinical and scientific evidence, encouraging collaboration among experts, residents, and fellows. This comprehensive program also creates opportunities for engagement with companies involved in imaging, artificial intelligence, genetic testing, and novel therapeutics, promoting innovation and educational impact across the field of Uro-oncology.

Faculty

Vipul Patel, MD
Marcio Moschovas, MD, PhD
Brian Miles, MD
Guru Sonpavde, MD
Raj Pruthi, MD
Carlos Alamani, MD
Victoria Bird, MD
Bridget Koontz, MD
Andrew F, MD
Spiegle, MD
Daher Chade, MD
Christopher Russel, MD
Justin Emtage, MD
Eleny Efstathiou, MD
Maha H, MD
Raju Thomas, MD
Zach Smith, MD

We will add more faculty

7:50-8:00- Welcome and introduction to the course (B. Miles, M. Moschovas, Raju Thomas, V. Patel)

8:00-8:20 State-of-the-Art in Prostate Cancer (2025–2026)

Recent updates from NCCN, AUA, and EAU guidelines; integration of PSMA PET, genomics, and radioligand therapy into standard of care. **Iulia Andras**

8:20- 9:40 Module 1- Prostate cancer screening, diagnosis, and Imaging

Panel: (Raju Thomas, J. Davis, Speagle, Victorya Bird, Gustavo Ayala, Punnen, Chiara Maria)

10 min each lecture

- Prostate cancer screening and negative impacts of non-screening recommendations (DOI: 10.1056/NEJMoa2503223)- **B. Miles**
- Liquid Biopsy in Non-Metastatic Prostate Cancer: Clinical Evidence and Future directions. **Chiara Maria**
- Genetic tests applications in PCa diagnosis and management (Decipher, 4k, PHI, GPS, urinary markers, exosomes, etc)- **Mary PA**
- Current role of MRI and PET Scan in prostate cancer diagnosis and staging (PSMA, Axumin, Fluoride, etc)- **Speagle**
- Current role of Artificial Intelligence in prostate cancer detection and image interpretation -**Victoria Bird**
- Prostate biopsy techniques (transrectal, transperineal, US fusion, MRI fusion): Which one should I do? **B. Miles**
- Current role of Artificial Intelligence in optimizing the Pathological analysis- **Gustavo Ayala**

9:40- 9:50 Discussion

Key Evidence discussed in the section: proPSMA, PRECISION, MRI-FIRST, PROMIS trials; EAU 2025 guidelines.

9:50-10:50 Module 2- Localized and Intermediate-Risk Localized Prostate Cancer

Panel: L.Klotz, M. Moschovas, Andrew Farach, Zach Smith

- Active surveillance: optimal candidates, protocols, and when to start treatment. Is Gleason 7 a safe candidate for AS? **L. Klotz**
- Surgical outcomes for localized PCa: oncologic and functional data from high-volume centers **Justin Emtage**
- Advances in radiotherapy to treat localized disease: moderate vs. ultra-hypofractionation (CHHiP, PACE-B, HYPO-RT-PC) **Andrew Farach**
- Focal Therapy applications to treat localized disease (Selection criteria, outcomes, and follow-up protocols) **Victoria Bird**

Key Evidence discussed in the section: PROTECT (15-year update), Canary PASS, PIVOT, SPCG-4 trials.

10:50-11:00 AM Discussion

11:00- 12:00 Module 3- High-Risk and Locally Advanced Prostate Cancer

Panel: Eleny Efstathiou, Bridget Koontz, J. Davis, Andrew Farach, Karin Toujier

- Genomic test applications in high-risk and patients with family history of PCa: When should I order? **Eleny Efstathiou**
- What's the treatment of choice in high-risk disease: surgery vs radiation therapy (plus ADT) ? (Radiation oncologist Standpoint) **Bridget Koontz**
- What's the treatment of choice in high-risk disease: surgery vs radiation therapy (Surgeon standpoint) **J. Davis**
- The role of post-prostatectomy radiation in high-risk disease based on clinical, pathologic and molecular characteristics **Andrew Farach**
- The role and extent of lymph node dissection in the PET-PSMA ERA **Karin Toujier**

12:00-12:10AM Discussion

Panel: Eleny Efstathiou, B. Miles, Bridget Koontz, Victoria Bird, Chiara Maria

12:10-12:40 Clinical cases of HG PCa: multidisciplinary approach. M. Moschovas

Key Evidence discussed in the section: STAMPEDE, PEACE-1, ATLAS, PROTEUS, ARNEO,NADIR trials.

12:40- 1:10 PM Lunch Break

1:10- 2:20PM Module 4- Recurrent Disease After Local Treatment

Panel: Guru Sonpavde, Bridget Koontz, Gustavo Ayala, Justin Emtage

- Applications of PSMA Pet or other radiotracers in staging PCa recurrence. Should PSMA-positive lesions be biopsied before salvage **Justin Emtage**
- Biochemical recurrence after RP: (**Guru Sonpavde?**)
 - When to offer observation ?
 - When to offer isolated XRT ?
 - When to offer XRT combined with ADT ?
 - When to offer systemic treatment ?
- Selecting the best salvage treatment after radiotherapy failure for localized prostate cancer? Surgery vs. RT vs. Ablation **Marcio Moschovas**
- Managing PCa with lymph node recurrence: how to optimize results? Surgery vs. RT (with or without ADT-based regimens) protocols. **Zach Smith**

2:00-2:20PM Clinical cases of recurrent PCa: multidisciplinary approach.

Key Evidence discussed in the section: EMPIRE-1, CONDOR, SPPORT, GETUG-AFU 16 trials

2:20-2:30 PM Discussion

2:30- 3:20 PM Module 5- Metastatic disease

M1CSPC Oligometastatic:

Panel: Eleny Efstathiou, Guru Sonpavde, Daher Chade

- Definition and evolution of the OMD concept. **Eleny Efstathiou**
- What's the optimal treatment of metachronic oligometastatic disease:
 - Focal treatment vs systemic treatment vs both **Guru Sonpavde**
- The role of local treatment including radiation therapy or surgery in low-volume metastatic disease **Daher Chade**
- **Clinical cases of oligometastatic PCa: multidisciplinary approach.**

Key Evidence discussed in the section: ORIOLE, STOMP, EXTEND, and DELINEATE trials.

Discussion: 3:20- 3:30

3:30PM-5:30PM Module 6- Metastatic disease

Panel: Carlos Alamani, Eleny Efstathiou, **YAU-member**, Spiegler

3:30- 4:00 PM M1CSPC

- 15 min: Ongoing studies and literature evaluating new agents beyond ADT in the metastatic setting **YAU-member**
- 15 min: Optimal systemic management of low and high -volume metastatic castration-sensitive PCa **Carlos Alamani**

4:00-5:00 M1CRPC

- 12min PARP inhibitors in M1CRPC: trials, results, and best candidates PROfound, PROpel, MAGNITUDE, TALAPRO 2 data. **Eleny Efstathiou**
- 12min Radioligand therapy (177Lu-PSMA-617, Ac-225): patient selection, sequencing, and safety. **Spiegler**
- 12min Ongoing studies evaluating new agents in the M1CRPC setting: **Carlos Alamani**
- **20min Clinical cases of M1CRPC: multidisciplinary approach.**

Key Evidence discussed in the section: ARASENS, ENZAMET, TITAN, PSMAfore, VISION, PROpel.

Closing Section 5:00PM

*****As soon as we will have several community urologists, residents and fellows, it is important to teach and explain the best protocols of AS, when to refer for PSMA PET, genomic testing, or advanced systemic therapy.**

